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Abstract
Background and aims: The spectrum of Coronavirus disease-2019 (COVID-19) has been clinically deﬁned from
asymptomatic carriers to critical illness. Different inﬂammatory markers have been used to account for the severity and
outcomes of this disease in different settings. Our study aims to investigate the role of these inﬂammatory markers in
deﬁning COVID-19 severity.
Methods: This cross-sectional study included 200 conﬁrmed cases of COVID-19. Inﬂammatory markers including
lymphocyte count, D-Dimers, Ferritin, CRP, LDH were noted at admission. The moderate-to-critical disease was deﬁned
according to the WHO criteria. Descriptive statistics were applied. ManneWhitney U-test was applied to compare the
difference of markers between moderate-severe and critical patients. ROC was plotted to determine the cut-off values of
these markers. Binary logistics regression analysis was used to assess which markers signiﬁcantly predict the severity of
COVID-19.
Results: A D-dimer value of >775 ng/ml and LDH >495 U/L had a sensitivity of 72.9% and 79.2% and speciﬁcity of 57.9%
and 53.6% respectively for critical COVID-19 illness. CRP levels of >100.5 mg/dl has a sensitivity of 66.7%. All inﬂammatory markers were signiﬁcantly higher in a critical group of patients (p < 0.05) except for lymphopenia. Binary logistics
regression analysis shows that LDH levels and D-dimers were only signiﬁcant predictors of severity in COVID-19 patients.
Conclusion: Inﬂammatory markers at admission are very useful in deﬁning the severity of COVID-19 in addition to the
clinical criteria. This is also useful in predicting adverse outcomes.
Keywords: COVID-19, Inﬂammatory markers, Ferritin levels, Lactate dehydrogenase, C-reactive protein

1. Introduction

A

t the end of the year 2019, a myriad of patients presented with a similar and unique
acute respiratory illness of unknown origin in the
Wuhan city of China.1 The causative agent of this
ambiguous and deadly respiratory illness was
identiﬁed as severe acute respiratory syndrome
coronavirus-2 (SARS-CoV-2) and the disease was
named Coronavirus 2019 disease (COVID-19) which
has resulted in a global pandemic.1,2

COVID-19 shows an extremely broad spectrum of
clinical manifestations ranging from mild or
asymptomatic disease to moderate-to-critical illness
in severe infection.3 Patients with severe disease
experience cytokine storm which is trigged due to
an systemic inﬂammatory response syndrome.3,4
The wrath of this cytokine storm acutely ravages
multiple organs including the respiratory system,
ultimately translating into hypoxia, respiratory
distress, acute renal failure, shock, or even sepsis.4
These clinical manifestations are regarded as the
hallmark of severe COVID-19 infection that
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signiﬁcantly increases the risk of mortality.5,6 Such
patients require a higher level of medical care with
intensive vital monitoring, oxygen therapy, pharmacological interventions, and in some cases invasive mechanical ventilation.5 Thus, categorization of
the patients into mild, moderate, severe, or critical
COVID-19 disease becomes of utmost importance
for utilization of intensive medical care. The World
Health Organization (WHO) has clinically classiﬁed
COVID-19 as mild, moderate, severe, and critical
COVID-19 illness based on a spectrum of different
clinical manifestations.7 Even though this system of
classiﬁcation is widely accepted by the medical
fraternity, it requires a thorough clinical assessment
of the patient and a high level of physician's clinical
skill. This requires the need for speciﬁc laboratory
markers that may complement the current clinical
classiﬁcation for appropriate risk stratiﬁcation of
patients.
Previous studies have shown that C-reactive protein (CRP), D-dimers, lactate dehydrogenase (LDH),
and interleukin-6 levels can be helpful in the prediction of adverse outcomes in patients with severe
COVID-19 infection.3e5,8 Nonetheless, the use of
these inﬂammatory markers in determining the
disease severity at admission is still an area of active
medical research.8 Therefore, owing to the
increasing burden of the disease, there is an urgent
need for appropriate risk stratiﬁcation of patients
based on the laboratory parameters for optimal
medical management of COVID-19 patients.
Therefore, this research aims to investigate the role
of various inﬂammatory markers (D-dimers, lactate
dehydrogenase, C-reactive protein, ferritin, and
lymphocyte count) at admission in determining the
severity of COVID-19. The signiﬁcance in outcomes
of SARS-CoV-2 associated pneumonia due to the
increased levels of such biomarkers upon admission
might help complement the clinical classiﬁcation for
appropriate risk stratiﬁcation.

2. Methods
This single-centered retrospective cross-sectional
study was conducted from May 2020 till June 2020 at a
designated COVID-19 center, Benazir Bhutto Hospital, Rawalpindi, Pakistan. All patients with a
conﬁrmed diagnosis of COVID-19 based on highresolution computed tomography scan (HRCT) and
ABI 7500 RT-PCR detection system after RNA
extraction (Qiagen Viral RNA Mini Kit). Patients with
ambiguous laboratory reports and clinically mild
disease as per WHO clinical criteria were subjected to
exclusion. The exclusion criteria ensured that only
patients with moderate to severe and critical patients

are included in the study. Thereafter, 200 patients
satisfying the inclusion and exclusion criteria were a
part of the ﬁnal analysis. WHO sample size calculator
was used to calculate the sample size.
Demographic details, clinical characteristics, and
laboratory data were collected from patient ﬁles and
computer records on a speciﬁed proforma. The
clinical disease severity was deﬁned as per WHO
criteria into moderate, severe, critical with ARDS,
and Critical with Sepsis/Septic shock.7
Numerical data were represented as mean ± standard deviation and median (range) while categorical
variables were represented as frequencies (percentages). The normality of the data set was determined
using the KolmogoroveSmirnov test. The median Ddimer, LDH levels, CRP levels, ferritin levels, and 1/
lymphocyte count (as a surrogate for lymphopenia)
were calculated. ManneWhitney U-test was used to
compare the various inﬂammatory markers across
disease severity. ROC curve was plotted to determine
the cut-off sensitivity and speciﬁcity of various inﬂammatory markers across disease severity. Data
were analyzed using SPSS version 25. Ethical
approval was solicited from the Institutional Research
Forum of Rawalpindi Medical University before
securing access to patient data.

3. Results
The current study analyzed 200 patients with
conﬁrmed SARS-CoV-2 infection. The mean age of
the study participants hovered at 53.82 ± 12.84 years
and ranged between 20 and 90 years. Dyspnea and
fever were the most common presenting symptoms
occurring in 89.5 and 50% of the patients respectively. Other baseline characteristics of the study
participants are elucidated in Table 1.
Shairpiro Wilk test was used to assess the
normality of data which showed a p value less than
0.001. Therefore, median with intraquartile ranges
were used to delinate the values of various laboratory markers. There was a signiﬁcant different between the D-dimers, LDH, and CRP levels of severe
vrsus critical COVID-19 patients. Table 2 delineates
the comparison of various laboratory parameters in
moderate to severe and critical COVID-19 patients.
The receiver operating characteristics (ROC)
analysis shows that D-dimers and LDH levels had
better sensitivity and speciﬁcity than other inﬂammatory markers. LDH levels at a cut-off value of 495
U/L had a sensitivity of 79.2% and speciﬁcity of
53.6%. The ROC curve analysis of a myriad of inﬂammatory markers (LDH, D-Dimers, Ferritin,
CRP, and 1/Lymphocyte count) are elucidated in
Table 3.

Table 1. An elucidation of patients’ baseline demographic characteristics.
Parameters
Gender
Symptom Analysis

Comorbidities

Severity (According to WHO deﬁnition)

Male
Female
Fever
Dyspnea
Dry Cough
Sore throat
Diarrhea
Diabetics
Hypertension
Ischemic Heart Disease
Chronic Obstructive Pulmonary Disease
Asthma
Rheumatoid Arthritis
Chronic Kidney Disease
Hepatitis B/C
Hypothyroidism
Moderate to Severe
Critical

Frequency (n)

Percentages (%)

126
74
100
179
46
19
11
94
94
37
9
11
3
7
7
7
152
48

63%
37%
50%
89.5%
23%
9.5%
5.0.6%
47%
47%
18.5%
4.5%
5.5%
1.5%
3.5%
3.5%
3.5%
76%
24%

Table 2. Comparison of median values of a myriad of laboratory parameters in both groups.
Parameters

Moderate to severe
Illness (n ¼ 152)

Critical Illness
(n ¼ 48)

P-valuea

D-dimers (ng/mL)
Ferritin Levels (ng/mL)
CRP Levels (mg/dL)
LDH Levels (U/L)
1/Lymphocyte percentage (Lymphopenia)

600 (100e3200)
550 (198e3454)
100 (2e604)
457 (196e2000)
0.083 (0.04e0.50)

910 (100e4200)
700 (200e3454)
145 (45e2000)
668.5 (196e2500)
0.083 (0.04e0.14)

<0.001
0.069
0.001
<0.001
0.206

a

Mann Whitney U Test.

Table 3. Tabulation of ROC curve characteristics for various inﬂammatory markers.
Parameter

Area

P-value

95% CI

Selected Cutoff value

Sensitivity
at Cut-off

Speciﬁcity
at cut-off

D-dimers (ng/mL)
Ferritin Levels (ng/mL)
CRP Levels (mg/dL)
LDH Levels (U/L)
1/Lymphocyte percentage
(Lymphopenia)

0.701
0.587
0.662
0.707
0.560

<0.001
0.070
0.001
<0.001
0.208

0.613e0.788
0.489e0.685
0.575e0.749
0.621e0.793
0.474e0.647

775.0
517.5
100.5
495.0
0.690

72.9%
70.8%
66.7%
79.2%
79.2%

57.9%
45.4%
56.6%
53.6%
40.8%

Binary logistics regression analysis shows that
LDH levels and D-dimers were only signiﬁcant
predictors of severity in COVID-19 patients. This is
shown in Table 4.
Fig. 1 elucidates ROC for inﬂammatory markers
against COVID-19 clinical severity.

speciﬁc and sensitive in deﬁning the severity of
COVID-19 as compared to 1/lymphocyte count
(lymphopenia) ferritin, and CRP levels. The latter
had good sensitivity but relatively lower speciﬁcity.

4. Discussion

Parameter

P value

95% CI

Elevation of inﬂammatory markers in the body is
the hallmark of initiation of cytokine storm in acute
SARS-CoV-2 infection and is associated with
adverse outcomes.9 The results of our study elucidated that elevated D-dimers (cut off: 775 ng/mL)
and serum LDH levels (cut off: 495 U/L) are more

Odd's
ration

D-dimers (ng/mL)
Ferritin Levels (ng/mL)
CRP Levels (mg/dL)
LDH Levels (U/L)
1/Lymphocyte percentage
(Lymphopenia)

1.001
0.999
1.002
1.002
0.001

0.001
0.109
0.166
0.006
0.412

1.001e1.002
0.999e1.002
0.999e1.005
1.000e1.003
0e64,845.6

Table 4. Results of binary logistics regression analysis performed for all
inﬂammatory markers.
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Fig. 1. Receiver operation curve (ROC) for inﬂammatory markers against COVID-19 clinical severity.

D-dimers are cross-linked ﬁbrin degradation
products that play an important prognostic role in
determining the severity of multiple systemic and
inﬂammatory disorders including venous thromboembolism (VTE) and COVID-19.10 The prognostic
value of D-dimers in predicting adverse outcomes in
patients with severe SARS-CoV-2 infection has also
been validated in another retrospective analysis
where a cut-off value of greater than 501 ng/mL after
COVID-19 treatment predicted increased odds of
mortality and adverse outcomes.4 Similarly, a
caseecontrol study demonstrated that per unit increase in D-dimers signiﬁcantly increases the risk of
mortality in COVID-19.11 The same study also
demonstrated that elevated D-dimers have a sensitivity of 88% and speciﬁcity of 71.3% in predicting the
in-hospital mortality in COVID-19 patients.11 Even
though it exhibits high sensitivity and speciﬁcity for
predicting mortality and mechanical ventilation, the
results of our study indicate that elevated D-dimers
at admission have moderate sensitivity (72.9%) and
speciﬁcity (57.9%) for deﬁning the severity of
COVID-19.
LDH is also an important prognostic indicator for
severe SARS-COV-2 infection and our results
delineate that elevated levels of greater than 495 U/L
can help deﬁne the severity of COVID-19 with a
sensitivity of 79.2% and speciﬁcity of 53.6%.

Previously published literature also indicates an association of elevated LDH levels with increased
clinical severity.8,12,13 A study from Italy validates our
study ﬁndings demonstrating a sensitivity of 75%
and a speciﬁcity of 70% at a cut-off value of 450 U/L of
LDH for accurate identiﬁcation of moderate-to-severe acute respiratory distress syndrome caused by
SARS-CoV-2.12 However, a single-centered retrospective observational study from China indicated a
high speciﬁcity of 96% and a sensitivity of 68.9% for
LDH in the identiﬁcation of severe COVID-19
cases.13 These ﬁndings further augment the need for
conduction of prospective cohort studies for the
determination of the accurate prognostic value of
LDH as a marker of severity in COVID-19.
In regards to CRP levels, our study demonstrated
a high sensitivity of 83.3% but a low speciﬁcity of
36.2% at a cut-off value of 95 mg/dL. A singlecentered study from the United Kingdom demonstrated that CRP levels of more than 97 mg/dL
accurately predicted the need for mechanical
ventilation in 80% of the patients.3 Another analysis
while comparing the results of 12 studies on CRP
levels in COVID-19 validated the role of this acute
phase reactant in the identiﬁcation of severe SARSCoV-2 infection.14 Nonetheless, its low speciﬁcity
questions its use as a sole determinant of COVID-19
severity.8,12

The results of our study further show that lymphopenia and ferritin levels have moderate sensitivity and speciﬁcity for deﬁning COVID-19 severity.
Published literature shows that lymphocytopenia at
admission is associated with more severe disease
and frequent ICU admissions (OR ¼ 3.4, 95%
CI ¼ 1.06e10.96).15 Furthermore, experts recommend the inclusion of lymphopenia in the guidelines for diagnostic and therapeutic management of
COVID-19.16 Similarly, multiple studies have
advocated the use of serum ferritin levels for accurate prediction of disease severity.17e19
A retrospective cross-sectional study design and
consecutive sampling technique account for a few
limitations of our study. Nonetheless, the results of
our study must be given serious considerations as
there is an urgent need to determine the disease
severity using inﬂammatory markers. Further prospective cohort studies and meta-analysis on the
topic will aid in the curation of speciﬁc guidelines to
aid in clinical and laboratory diagnosis of COVID-19.

5. Conclusion
D-dimer and serum LDH levels truly play a role as
early prognostic factors in determining the severity of
COVID-19. Therefore, increased levels at the time of
admission may indicate severe disease which can
translate into adverse outcomes. Serum ferritin, lymphocytopenia had greater sensitivity; however, their
low speciﬁcity weakens their value as prognostic indicators for worsening COVID-19 infection. LDH
levels and D-dimers were only signiﬁcant predictors
of severity in COVID-19 patients. Further studies are
required to validate these ﬁndings.
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